Hanmi Science has filed a patent for a method of treating liver disease using a triple agonistic long-acting conjugate or a triple agonist in combination with a farnesoid X receptor agonist and an acetyl-CoA carboxylase inhibitor. The patent claims a specific chemical formula for the long-acting conjugate and provides a detailed amino acid sequence for the triple agonist. GlobalData’s report on Hanmi Science gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Hanmi Science Co Ltd - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Hanmi Science, Hormone-based therapies for metabolic disorders was a key innovation area identified from patents. Hanmi Science's grant share as of September 2023 was 36%. Grant share is based on the ratio of number of grants to total number of patents.

The patent is filed for a method of treating liver disease

Source: United States Patent and Trademark Office (USPTO). Credit: Hanmi Science Co Ltd

A recently filed patent (Publication Number: US20230310630A1) describes a method for treating liver disease using a pharmaceutical composition. The method involves administering the composition to a subject in need, which includes a triple agonistic long-acting conjugate or triple agonist, a farnesoid X receptor agonist, and a pharmaceutically acceptable excipient. The triple agonistic long-acting conjugate is a substance with a specific chemical formula, including a linker and an immunoglobulin Fc region. The composition also includes a peptide with a specific amino acid sequence.

The patent claims provide detailed information about the specific amino acid sequences and variations that can be used in the composition. The amino acid sequences include various combinations of amino acids such as histidine, glycine, glutamic acid, leucine, cysteine, and others. The patent also mentions the formation of a lactam ring between glutamic acid and lysine in some cases.

The patent further describes the use of a farnesoid X receptor agonist in combination with the pharmaceutical composition. Examples of farnesoid X receptor agonists mentioned in the patent include Cafestol, Chenodeoxycholic acid, Obeticholic acid, and others.

The method described in the patent is applicable for the treatment of liver diseases, specifically non-alcoholic fatty liver disease (NAFLD) and cholestatic liver disease. NAFLD encompasses various conditions such as simple steatosis, liver inflammation, non-alcoholic fatty liver, non-alcoholic steatohepatitis, liver cirrhosis, liver fibrosis, liver decompensation, and hepatocellular carcinomas. Cholestatic liver diseases include primary biliary cirrhosis and primary sclerosing cholangitis.

Additionally, the patent mentions the possibility of combining the pharmaceutical composition with an acetyl-CoA carboxylase inhibitor, which can further enhance the treatment of liver diseases.

Overall, the patent provides a detailed method for treating liver diseases using a specific pharmaceutical composition, including the use of triple agonistic long-acting conjugates or triple agonists, farnesoid X receptor agonists, and specific amino acid sequences. The method shows potential for the treatment of non-alcoholic fatty liver disease and cholestatic liver disease.

To know more about GlobalData’s detailed insights on Hanmi Science, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies